Aether Industries Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹21.6K Cr

CEM (Contract Exclusive Manufacturing) and CRAMS (Contract Research and Manufacturing Services) are expected to contribute over 70% of revenue in the next couple of years, indicating strong growth in these high-margin segments. Aether expects continued strong growth with expanding Contract Exclusive Manufacturing (CEM) and CRAMS models, aiming for these two segments to contribute over 70% of revenue in the next couple of years.

From Aether Industries Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Price

₹1,626

Market Cap

₹21.6K Cr

P/E Ratio

90.0

How does Aether Industries Ltd rank in Chemicals & Petrochemicals?

Compare Aether Industries Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 2Margin: Rank 3

View Chemicals & Petrochemicals leaderboard →

Aether Industries Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹305 Cr, net profit ₹54 Cr.

Full financials →

📊 Revenue & Sales Performance

Rank 2

→CEM (Contract Exclusive Manufacturing) and CRAMS (Contract Research and Manufacturing Services) are expected to contribute over 70% of revenue in the next couple of years, indicating strong growth in these high-margin segments.
→Site 3++ block ramp-up and Site 5 commissioning are on schedule, which will increase production capacity and sales in upcoming quarters.
→New customer onboarding and more than nine customer audits cleared in Q1 FY27 signal a strong and growing order pipeline.
→Organic growth in the oil and gas segment, which already accounts for around 20% of revenue and expected to increase further.
→Semiconductor and material science segments have high growth potential with multiyear R&D programs underway, including new product commercialization starting Q2 FY27.
→Strategic partnership with Dow targets the billion-dollar silicone market in India, aiming for long-term technology commercialization and growth.
→Progressive working capital management and capex (~INR 3,000-3,500 million for FY27) support expansion and revenue growth.

📈 Profitability & Margins

Rank 3

→Aether expects continued strong growth with expanding Contract Exclusive Manufacturing (CEM) and CRAMS models, aiming for these two segments to contribute over 70% of revenue in the next couple of years.
→EBITDA margins for CEM currently range between 28%-30%, with rising margins as the mix shifts toward higher-margin CEM contracts.
→The company is scaling new capacities (Site 3++ and Site 5), which are expected to improve working capital efficiency and revenue realization.
→Oil & Gas segment is already about 20% of business and is expected to grow further in coming years.
→Semiconductor and material science segments are in multiyear R&D/commercialization phases, with commercial production targeted around late 2026/early 2027, offering future margin expansion.
→The partnership with Dow Chemical is a landmark opportunity that may open up significant future revenue streams in advanced silicones.
→Q1 FY27 PAT grew 33% YoY, signaling strong profitability momentum.

See what Aether Industries Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→Total capex for Q1 FY27 was INR 943 million.
→Capex expected for FY27 is between INR 3,000 million to INR 3,500 million.
→FY27 capex primarily allocated to Site 5 and the new R&D site, which is progressing well.
→Expansion includes Site 3++ ramp-up and capacity scaling at Site 5.
→Strategic investments include building manufacturing capacity near Surat at Panoli (Magnum Site 5).
→Focus on concurrent expansions in R&D, pilot plants, and manufacturing assets.
→Investment aligned with technology development, including multi-year R&D programs (e.g., Dow partnership for silicone technology).
→Emphasis on capital efficiency and working capital discipline alongside capex.

💰 Fundraising & Capital Structure

No information

→There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
→The company discussed ongoing capex plans with expected expenditure between INR 3,000 million to INR 3,500 million in FY27, primarily for Site 5 and a new R&D site.
→The management emphasized working capital discipline and sustained reduction in working capital intensity but did not mention any new financing.
→No direct comments on fundraising activities (debt or equity) were provided during the Q&A or closing remarks.
→When asked about investment size in R&D (specifically related to Dow collaboration), the company declined to disclose details but confirmed significant investment. However, this is related strictly to operational investments, not fundraising.

See what Aether Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

Yes

→The company does not disclose detailed order book or product count for competitive reasons at this stage. (Page 14)
→Commercial sales for new LSM products at Site 5 started in Q1 FY27, with revenue contribution expected from Q2 FY27. (Page 14)
→Order buildup is in progress for new LSM products across pharmaceutical, agrochemical, and material science sectors. (Page 14)
→The CEM and CRAMS pipelines are described as the deepest ever, with strong order visibility and rising urgency from Western customers in FY27. (Page 7)
→No specific numbers or values for pending orders were disclosed publicly. (Page 14, 7)

Key Metrics

2 of 5 growth signals positive in the Q1 FY27 call.

Revenue

Rank 2

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

Yes

How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aether Industries Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

What Aether Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Deepak Fertilisers & Petrochemicals Corp Ltd (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…
SUDARSCHEM (Q1 FY27)
Volume growth has been modest (~6% in Q1), with confidence rooted in business recovery and value capture initiatives (Page 6). Key concall takeaways from…

Compare:vs Solar Industries India Ltd vs PIDILITIND vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aether Industries Ltd Q1 FY27 results?

What is Aether Industries Ltd share price analysis?

Aether Industries Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 90.0 with a market cap of ₹21,590 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aether Industries Ltd planning capital expenditure?

Total capex for Q1 FY27 was INR 943 million.

Keep Aether Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.